Salix scores another FDA green light with approval for angioedema med Ruconest

In its second FDA nod this week, Salix Pharmaceuticals ($SLXP) won the go-ahead for Ruconest, its first-in-class treatment for a rare genetic disease, hereditary angioedema. On Monday, the agency approved broader use of the constipation drug Relistor in patients using opioids for chronic pain. Story

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.